CN110665052A - Puerarin hydrogel wound auxiliary material - Google Patents
Puerarin hydrogel wound auxiliary material Download PDFInfo
- Publication number
- CN110665052A CN110665052A CN201911014717.0A CN201911014717A CN110665052A CN 110665052 A CN110665052 A CN 110665052A CN 201911014717 A CN201911014717 A CN 201911014717A CN 110665052 A CN110665052 A CN 110665052A
- Authority
- CN
- China
- Prior art keywords
- puerarin
- hydrogel
- hydrogel wound
- stirring
- wound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/216—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
Abstract
The invention provides a preparation method of puerarin hydrogel wound auxiliary material, which comprises the steps of dissolving puerarin in glycerol, adding sodium alginate aqueous solution, adding nostoc polysaccharide, stirring uniformly, slowly dripping the mixture into liquid paraffin, and continuously stirring for a first time period after dripping is finished to fully and uniformly mix a water phase and an oil phase; adding curing agent by using a peristaltic pump, and continuously stirring for a second time period after the dropwise adding is finished to obtain the puerarin hydrogel. The invention takes puerarin and nostoc polysaccharide as raw materials to prepare the hydrogel with good wound healing effect, has high absorption efficiency and good wound healing effect, and the puerarin is used for the wound healing material for the first time, has obvious effect and has wide application prospect.
Description
Technical Field
The invention relates to the technical field of natural medicines, in particular to a puerarin hydrogel wound auxiliary material.
Background
The small molecule hydrogel is a novel hydrogel appearing in recent years, is formed by self-assembling small molecules through non-covalent bonds, and has the characteristics and advantages of high biocompatibility, easy degradation, easy absorption and the like. Therefore, the compound has excellent application prospect in the fields of cell culture, tissue engineering, drug controlled release, regenerative medicine and the like. Small molecule hydrogels are mostly made of small molecules such as polypeptides, amino acid derivatives, and heterocyclic compounds by self-assembly. However, these compounds are chemically synthesized and do not exist in nature. The small molecule hydrogel formed by the compounds needs to be verified in the clinical practical application through complex and rigorous experiments to verify the biocompatibility and the bioactivity. This adds significantly to the complexity, cost, and development cycle of hydrogel preparation. The ideal small molecule hydrogel is preferably self-assembled from compounds that have been validated for use in humans. For example, the only small molecule hydrogel approved by the FDA for drug sustained release is self-assembled from lanreotide. Before 2009 lanreotide was injected in solution for the treatment of acromegaly, requiring intramuscular injections once a day. Later, it was found that lanreotide self-assembles to form a small molecule hydrogel in a jelly-like shape at elevated concentrations (above 2%), and thus has been approved by the FDA in the form of a new dosage form of a sustained release hydrogel for drugs. At present, the lanreotide hydrogel can slowly release the medicine for 1 month by subcutaneous injection once. Therefore, if a hydrogel formed of small molecules that have been approved for use in humans is available, it is of great importance for long-lasting administration of the drug.
Puerarin is also known as puerarin. Is isoflavone derivative separated from radix Puerariae with dilating coronary effect. Is present in root of Pueraria lobata Ohwi of Leguminosae. Has antipyretic, tranquilizing, coronary blood flow increasing, and acute myocardial hemorrhage caused by posterior pituitary. Can be used for treating coronary heart disease, angina pectoris, and hypertension.
Disclosure of Invention
The invention provides a puerarin hydrogel wound auxiliary material and a preparation method thereof, and aims to provide the puerarin hydrogel wound auxiliary material.
The invention provides a preparation method of puerarin hydrogel wound auxiliary material, which comprises the steps of dissolving puerarin in glycerol, adding sodium alginate aqueous solution, adding nostoc polysaccharide, stirring uniformly, slowly dripping the mixture into liquid paraffin, and continuously stirring for a first time period after dripping is finished to fully and uniformly mix a water phase and an oil phase; adding curing agent by using a peristaltic pump, and continuously stirring for a second time period after the dropwise adding is finished to obtain the puerarin hydrogel.
As a further improvement of the invention, the curing agent is a 70 wt% ethanol solution of 0.1 wt% calcium chloride.
As a further development of the invention, the first time period is from 1 to 2h and the second time period is from 0.5 to 1.5 h.
As a further improvement of the invention, the adding flow rate of the curing agent is 0.1-0.2mL/min, and the stirring rotation speed is 1000-1500 r/min.
As a further improvement of the invention, the mass fraction of the sodium alginate in the sodium alginate aqueous solution is 0.5-1.5%; the puerarin hydrogel comprises 2-4 wt% of puerarin and 0.5-2 wt% of nostoc polysaccharide.
As a further improvement of the invention, 1 wt% of span-20 and 1.5 wt% of Tween-20 are also added into the liquid paraffin.
As a further improvement of the invention, the extraction method of the nostoc polysaccharide comprises the following steps: drying Nostoc sphaeroids Kutz, pulverizing to obtain fine powder, soaking in water for 24 hr, extracting with boiling water twice under the assistance of microwave, filtering, mixing filtrates, and evaporating in water bath to obtain extract with density of 2-3g/cm3Adding 95 wt% ethanol solution into the concentrated solution, stirring and cooling to obtain white precipitate, and filtering to obtain nostoc polysaccharide.
The invention further protects the puerarin hydrogel wound auxiliary material obtained by the preparation method.
As a further improvement of the invention, menthyl lactate, a cooling agent, is also added.
The invention further protects the application of the puerarin hydrogel wound auxiliary material in the field of wound healing.
The invention has the following beneficial effects: the invention takes puerarin and nostoc polysaccharide as raw materials to prepare the hydrogel with good wound healing effect, has high absorption efficiency and good wound healing effect, and the puerarin is used for the wound healing material for the first time, has obvious effect and has wide application prospect.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and for those skilled in the art, other drawings can be obtained according to these drawings without creative efforts.
FIG. 1 is a diagram of a group of wounds in test example 1 of the present invention;
FIG. 2 is a diagram of wounds from two groups in test example 1 of the present invention;
FIG. 3 is a diagram of three groups of wounds in test example 1 of the present invention;
fig. 4 is a diagram of an initial wound in test example 1 of the present invention.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
A preparation method of puerarin hydrogel wound adjuvant comprises:
dissolving puerarin in 100mL of glycerol, adding 0.5 wt% of sodium alginate aqueous solution, adding nostoc polysaccharide, stirring uniformly, slowly dripping the mixture into 100mL of liquid paraffin, and continuously stirring for 1h after dripping is finished to fully and uniformly mix a water phase and an oil phase; adding curing agent (70 wt% ethanol solution of 0.1 wt% calcium chloride) with a peristaltic pump at a flow rate of 0.1mL/min and a stirring speed of 1000r/min, and stirring for 0.5h to obtain puerarin hydrogel with a yield of 90%; the puerarin hydrogel comprises 2 wt% of puerarin and 0.5 wt% of nostoc polysaccharide.
The extraction method of nostoc polysaccharide comprises the following steps: drying and pulverizing Nostoc sphaeroids Kutz 100g to obtain fine powder, soaking in 100mL water for 24 hr, extracting with 300W microwave-assisted boiling water twice, filtering, mixing filtrates, and evaporating in water bath to obtain extract with density of 2g/cm3The concentrated solution of (A) is addedAdding 50mL of 95 wt% ethanol solution, stirring and cooling to obtain white precipitate, and filtering to obtain nostoc polysaccharide.
Example 2
A preparation method of puerarin hydrogel wound adjuvant comprises:
dissolving puerarin in 100mL of glycerol, adding 1.5 wt% of sodium alginate aqueous solution, adding nostoc polysaccharide, stirring uniformly, slowly dripping the mixture into 100mL of liquid paraffin, and continuously stirring for 2h after dripping is finished to fully and uniformly mix a water phase and an oil phase; adding curing agent (70 wt% ethanol solution of 0.1 wt% calcium chloride) with a peristaltic pump at a flow rate of 0.2mL/min and a stirring speed of 1500r/min, and stirring for 1.5h to obtain puerarin hydrogel with a yield of 92%; the puerarin hydrogel comprises 4 wt% of puerarin and 2 wt% of nostoc polysaccharide.
The extraction method of nostoc polysaccharide comprises the following steps: drying and pulverizing Nostoc sphaeroids Kutz 100g to obtain fine powder, soaking in 100mL water for 24 hr, extracting with 500W microwave-assisted boiling water twice, filtering, mixing filtrates, and evaporating in water bath to obtain a product with density of 3g/cm3Adding 50mL of 95 wt% ethanol solution into the concentrated solution, stirring and cooling to obtain white precipitate, and filtering to obtain nostoc polysaccharide.
Example 3
A preparation method of puerarin hydrogel wound adjuvant comprises:
dissolving puerarin in 100mL of glycerol, adding 1 wt% of sodium alginate aqueous solution, adding nostoc polysaccharide, stirring uniformly, slowly dropwise adding the mixture into 100mL of liquid paraffin (the liquid paraffin is added with 1 wt% of span-20 and 1.5 wt% of Tween 20), and continuously stirring for 1.5h after dropwise adding is finished, so that the water phase and the oil phase are fully and uniformly mixed; adding curing agent (70 wt% ethanol solution of 0.1 wt% calcium chloride) with a peristaltic pump at a flow rate of 0.15mL/min and a stirring speed of 1250r/min, and stirring for 1h after dripping to obtain puerarin hydrogel with a yield of 95%; the puerarin hydrogel comprises 3 wt% of puerarin and 1.5 wt% of nostoc polysaccharide.
Extraction of nostoc polysaccharideThe method comprises the following steps: drying and pulverizing Nostoc sphaeroids Kutz 100g to obtain fine powder, soaking in 100mL water for 24 hr, extracting with 400W microwave-assisted boiling water twice, filtering, mixing filtrates, and evaporating in water bath to obtain extract with density of 2.5g/cm3Adding 50mL of 95 wt% ethanol solution into the concentrated solution, stirring and cooling to obtain white precipitate, and filtering to obtain nostoc polysaccharide.
Example 4
A preparation method of puerarin hydrogel wound adjuvant comprises:
dissolving puerarin in 100mL of glycerol, adding 1 wt% of sodium alginate aqueous solution, adding nostoc polysaccharide and 0.5g of menthyl lactate, uniformly stirring, slowly dropwise adding the mixture into 100mL of liquid paraffin (the liquid paraffin is added with 1 wt% of span-20 and 1.5 wt% of tween-20), and continuously stirring for 1.5h after dropwise adding is finished, so that the water phase and the oil phase are fully and uniformly mixed; adding curing agent (70 wt% ethanol solution of 0.1 wt% calcium chloride) with a peristaltic pump at a flow rate of 0.15mL/min and a stirring speed of 1250r/min, and stirring for 1h after dripping to obtain puerarin hydrogel with a yield of; the puerarin hydrogel comprises 3 wt% of puerarin and 1.5 wt% of nostoc polysaccharide.
The extraction method of nostoc polysaccharide comprises the following steps: drying and pulverizing Nostoc sphaeroids Kutz 100g to obtain fine powder, soaking in 100mL water for 24 hr, extracting with 400W microwave-assisted boiling water twice, filtering, mixing filtrates, and evaporating in water bath to obtain extract with density of 2.5g/cm3Adding 50mL of 95 wt% ethanol solution into the concentrated solution, stirring and cooling to obtain white precipitate, and filtering to obtain nostoc polysaccharide.
Comparative example 1
Compared with example 3, no nostoc polysaccharide was added.
Comparative example 2
Compared with the example 3, the puerarin hydrogel has the mass fraction of 0.1 wt% of puerarin and the mass fraction of nostoc polysaccharide of 1.5 wt%.
Comparative example 3
Compared with the example 3, the puerarin hydrogel has the mass fraction of 3 wt% of puerarin and the mass fraction of nostoc polysaccharide of 0.1 wt%.
Comparative example 4
The technical parameters are different compared to example 3.
A preparation method of puerarin hydrogel wound adjuvant comprises:
dissolving puerarin in 100mL of glycerol, adding 1 wt% of sodium alginate aqueous solution, adding nostoc polysaccharide, stirring uniformly, slowly dropwise adding the mixture into 100mL of liquid paraffin (the liquid paraffin is added with 1 wt% of span-20 and 1.5 wt% of Tween 20), and continuously stirring for 0.5h after dropwise adding is finished, so that the water phase and the oil phase are fully and uniformly mixed; adding curing agent (70 wt% ethanol solution of 0.1 wt% calcium chloride) with a peristaltic pump at a flow rate of 0.5mL/min and a stirring speed of 500r/min, and stirring for 0.5h to obtain puerarin hydrogel with a yield of 75%; the puerarin hydrogel comprises 3 wt% of puerarin and 1.5 wt% of nostoc polysaccharide.
Test example 1 mouse wound healing test
Experimental animals: male rats were housed in an environment-adapted SPF scale in 30 animals, and after one week, they were randomly divided into 3 groups of 10 animals each. Each mouse has two holes, one is filled with medicine, and the other is filled with normal saline.
The experimental method comprises the following steps:
after anesthetizing the rat with 10% chloral hydrate, the rat was prone on the fixed plate, and a full-thickness wound (with epidermis and dermis removed) wound surface of 10mm in diameter was made on each of the left and right sides of the rat spine at approximately equivalent positions. The left wound served as a self-control group and was rinsed with 0.9% physiological saline; puerarin hydrogel is smeared on the right side wound. Feeding alone, applying the medicine 1 time daily for 12 days. And observing every day after operation, collecting pictures and measuring the wound area.
The administration method comprises the following steps: one group is coated with 2% puerarin hydrogel, two groups are coated with 3% puerarin hydrogel, three groups are coated with 4% puerarin hydrogel, and the blank group is coated with 0.9% normal saline. The medicine is applied 1 time daily for 2 days. And observing every day after operation, and collecting pictures.
The experimental results are as follows:
as shown in fig. 1 to 4, it can be seen from fig. 1 to 3 that the wound is significantly reduced after the puerarin hydrogel prepared in examples 1 to 3 of the present invention is applied on the wound for 12 days, wherein the puerarin hydrogel can rapidly and significantly promote the healing of the full-thickness wound on the back of the rat, and compared with the initial wound (fig. 4), the wound is significantly healed after 12 days.
Typical cases are as follows:
1. zhang XX, female, 55 years old, with a wound under the hind paw, 2.5 cm wide and 2 cm deep. The wound is injured for more than one year, the wound is not healed, the patient can not sleep due to pain at night, and the patient can see the patient for a plurality of times in a hospital in the market, so that the effect is not achieved after the medicine is taken. After the product of the invention in the embodiment 4 is used, the product has cool feeling after the first time of medication, is not painful immediately, can sleep at night and is completely healed after being used for one month.
2. Wang X, male, age 40, mostly burned on the fire on the surface of the feet to hurt the bones. The treatment is not good for more than 3 months. After two months of administration, the product of example 3 of the invention healed substantially completely.
3. The formula XX, female, 75 years old, had a wound on the hand and also seen in hospitals in county and city, after 1 treatment and 1 more month of application, the wound healed, and after 1 week of continuous use, the wound healed.
4. Zhu X, male, age 65, with cerebral infarction, deep burns of both lower legs, not good for more than 3 months, no good results after burns going to the municipal hospital for diagnosis and treatment. The product of example 1 of the invention was then used to heal after one and a half months.
5. Zhao XX, male, 50 years old, 5 cm wide in the middle of thigh, 2 cm deep and one wound, which is not good for a month in rural hospital. The wound was then healed with the product of example 4 of the invention, after approximately twenty days of application.
Compared with the prior art, the hydrogel with good wound healing effect is prepared by taking the puerarin and the nostoc polysaccharide as raw materials, has high absorption efficiency, good wound healing effect, quick response, safety, no side effect and mild and no irritation, and the puerarin is used as a wound healing material for the first time, has obvious effect and has wide application prospect.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents, improvements and the like that fall within the spirit and principle of the present invention are intended to be included therein.
Claims (10)
1. A preparation method of puerarin hydrogel wound adjuvant is characterized in that puerarin is dissolved in glycerol, added into sodium alginate aqueous solution, added with nostoc polysaccharide, stirred uniformly, slowly dripped into liquid paraffin, and stirred continuously for a first time period after dripping is finished, so that a water phase and an oil phase are fully and uniformly mixed; adding curing agent by using a peristaltic pump, and continuously stirring for a second time period after the dropwise adding is finished to obtain the puerarin hydrogel.
2. The method for preparing a puerarin hydrogel wound dressing according to claim 1, wherein the solidifying agent is 0.1 wt% calcium chloride in 70 wt% ethanol solution.
3. The method for preparing a puerarin hydrogel wound adjuvant according to claim 1, wherein the first time period is 1-2h, and the second time period is 0.5-1.5 h.
4. The method for preparing a puerarin hydrogel wound adjuvant according to claim 1, wherein the adding flow rate of the solidifying agent is 0.1-0.2mL/min, and the stirring rotation speed is 1000-1500 r/min.
5. The preparation method of the puerarin hydrogel wound adjuvant according to claim 1, wherein the mass fraction of sodium alginate in the sodium alginate aqueous solution is 0.5-1.5%; the puerarin hydrogel comprises 2-4 wt% of puerarin and 0.5-2 wt% of nostoc polysaccharide.
6. The method for preparing a puerarin hydrogel wound adjuvant according to claim 1, wherein span-20 in an amount of 1 wt% and tween-20 in an amount of 1.5 wt% are further added to the liquid paraffin.
7. The method for preparing a puerarin hydrogel wound adjuvant according to claim 1, wherein the nostoc polysaccharide is extracted by the following steps: drying Nostoc sphaeroids Kutz, pulverizing to obtain fine powder, soaking in water for 24 hr, extracting with boiling water twice under the assistance of microwave, filtering, mixing filtrates, and evaporating in water bath to obtain extract with density of 2-3g/cm3Adding 95 wt% ethanol solution into the concentrated solution, stirring and cooling to obtain white precipitate, and filtering to obtain nostoc polysaccharide.
8. A puerarin hydrogel wound adjuvant obtained by the preparation method according to any one of claims 1-7.
9. The puerarin hydrogel wound dressing of claim 8, wherein menthyl lactate, a cooling agent, is further added.
10. Use of a puerarin hydrogel wound dressing as claimed in claim 8 in the field of wound healing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911014717.0A CN110665052A (en) | 2019-10-24 | 2019-10-24 | Puerarin hydrogel wound auxiliary material |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911014717.0A CN110665052A (en) | 2019-10-24 | 2019-10-24 | Puerarin hydrogel wound auxiliary material |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110665052A true CN110665052A (en) | 2020-01-10 |
Family
ID=69083833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911014717.0A Pending CN110665052A (en) | 2019-10-24 | 2019-10-24 | Puerarin hydrogel wound auxiliary material |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110665052A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114796596A (en) * | 2022-04-22 | 2022-07-29 | 青岛大学 | Nanofiber hydrogel dressing loaded with salvia miltiorrhiza and radix puerariae and preparation process thereof |
| CN114376964B (en) * | 2021-12-16 | 2023-06-16 | 青岛科技大学 | Puerarin nanoparticle film-forming hydrogel preparation and preparation method thereof |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0459733A2 (en) * | 1990-05-29 | 1991-12-04 | Pronova Biopolymer As | Alginate gels |
| US20050271701A1 (en) * | 2000-03-15 | 2005-12-08 | Orbus Medical Technologies, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
| CN1833649A (en) * | 2006-01-11 | 2006-09-20 | 北京因科瑞斯生物制品研究所 | Jixuedai gel with action of promoting wound reunion, and prepn. thereof |
| CN101301303A (en) * | 2008-06-25 | 2008-11-12 | 重庆市中药研究院 | Uses of puerarin and derivatives thereof in preparing medicament |
| CN101653622A (en) * | 2009-09-11 | 2010-02-24 | 姚辉 | Amorphous aquagel pharmaceutic dressing of ShuangHuangLian and preparation method thereof |
| CN101658690A (en) * | 2009-09-25 | 2010-03-03 | 姚辉 | Officinal volatile argyi leaf oil dressing and preparation method thereof |
| CN105853843A (en) * | 2016-05-11 | 2016-08-17 | 刘静 | Pharmaceutical composition for clinical pediatric wound care and preparation method of pharmaceutical composition for clinical pediatric wound care |
| CN106492260A (en) * | 2016-12-22 | 2017-03-15 | 青岛琛蓝海洋生物工程有限公司 | A kind of alginate based aquagel dressing and preparation method thereof |
| CN106974905A (en) * | 2017-03-29 | 2017-07-25 | 南方医科大学 | A kind of Self-Assembled based on natural drug Puerarin |
| CN107335091A (en) * | 2017-08-31 | 2017-11-10 | 河南汇博医疗股份有限公司 | A kind of long acting antibiotic hydrogel and preparation method thereof |
| CN108744025A (en) * | 2018-05-30 | 2018-11-06 | 中山大学 | It is a kind of to be used to promote antioxygenic property hydrogel of wound healing and its preparation method and application |
-
2019
- 2019-10-24 CN CN201911014717.0A patent/CN110665052A/en active Pending
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0459733A2 (en) * | 1990-05-29 | 1991-12-04 | Pronova Biopolymer As | Alginate gels |
| US20050271701A1 (en) * | 2000-03-15 | 2005-12-08 | Orbus Medical Technologies, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
| CN1833649A (en) * | 2006-01-11 | 2006-09-20 | 北京因科瑞斯生物制品研究所 | Jixuedai gel with action of promoting wound reunion, and prepn. thereof |
| CN101301303A (en) * | 2008-06-25 | 2008-11-12 | 重庆市中药研究院 | Uses of puerarin and derivatives thereof in preparing medicament |
| CN101653622A (en) * | 2009-09-11 | 2010-02-24 | 姚辉 | Amorphous aquagel pharmaceutic dressing of ShuangHuangLian and preparation method thereof |
| CN101658690A (en) * | 2009-09-25 | 2010-03-03 | 姚辉 | Officinal volatile argyi leaf oil dressing and preparation method thereof |
| CN105853843A (en) * | 2016-05-11 | 2016-08-17 | 刘静 | Pharmaceutical composition for clinical pediatric wound care and preparation method of pharmaceutical composition for clinical pediatric wound care |
| CN106492260A (en) * | 2016-12-22 | 2017-03-15 | 青岛琛蓝海洋生物工程有限公司 | A kind of alginate based aquagel dressing and preparation method thereof |
| CN106974905A (en) * | 2017-03-29 | 2017-07-25 | 南方医科大学 | A kind of Self-Assembled based on natural drug Puerarin |
| CN107335091A (en) * | 2017-08-31 | 2017-11-10 | 河南汇博医疗股份有限公司 | A kind of long acting antibiotic hydrogel and preparation method thereof |
| CN108744025A (en) * | 2018-05-30 | 2018-11-06 | 中山大学 | It is a kind of to be used to promote antioxygenic property hydrogel of wound healing and its preparation method and application |
Non-Patent Citations (2)
| Title |
|---|
| SHAOHAN ZHANG ET AL: "Polydopamine/puerarin nanoparticle-incorporated hybrid hydrogels for enhanced wound healing", 《BIOMATERIALS SCIENCE》 * |
| 邢世瑞主编: "《宁夏中药志 上》", 31 March 2006, 宁夏人民出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114376964B (en) * | 2021-12-16 | 2023-06-16 | 青岛科技大学 | Puerarin nanoparticle film-forming hydrogel preparation and preparation method thereof |
| CN114796596A (en) * | 2022-04-22 | 2022-07-29 | 青岛大学 | Nanofiber hydrogel dressing loaded with salvia miltiorrhiza and radix puerariae and preparation process thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4987209B2 (en) | Use of biguanide derivatives for the manufacture of pharmaceuticals with scarring action | |
| CN102949709A (en) | External gel used for treating diabetic foot, and preparation method and application thereof | |
| WO2003009829A2 (en) | Antiemetic, anti-motion sustained release drug delivery system | |
| CN110665052A (en) | Puerarin hydrogel wound auxiliary material | |
| CN101292997B (en) | Pharmaceutical composition for treating empyrosis or gastric ulcer, and preparation method thereof | |
| CN105343032B (en) | A kind of Fenbendazole micro-capsule and preparation method thereof | |
| CN103705910B (en) | A kind of Ziconotide injection hypodermic implant and preparation method thereof | |
| WO2017129057A1 (en) | Medicament for use in treating diabetes | |
| CN105982882B (en) | A kind of externally applied drug and preparation process of optical active starting materials composition prescription therapeutic hemorrhoid | |
| CN101961318A (en) | Lappaconitine sustained release microspheres for injection and preparation method thereof | |
| KR20200112012A (en) | Compositions for skin wound healing and regeneration comprising (R)-Ginsenoside Rg3 | |
| CN102440957B (en) | Terlipressin acetate nasal cavity spray and preparation method thereof | |
| CN1695642A (en) | Compound gel of goldenlarch bark preparation method | |
| CN108079273A (en) | For postanesthetic nursing scrub cream of local skin and preparation method thereof | |
| CN106860509A (en) | The production technology of carpet bugle capsule | |
| CN101036660A (en) | Estrogen gelatin medicine and the method for preparing the same | |
| CN107951868B (en) | Muscone patch and preparation method and application thereof | |
| CN1238032C (en) | Tincture for curing acne and preparation method | |
| CN111632054A (en) | A pharmaceutical preparation for treating rheumatoid arthritis by transdermal administration, and its preparation method | |
| CN105213677A (en) | A kind of Chinese medicinal film for topical anesthesia and preparation method thereof | |
| CN112675228B (en) | Ointment for promoting wound healing and preparation method thereof | |
| JP3652865B2 (en) | Mixture of lactic acid condensate and composition containing the same | |
| CN114948852B (en) | Microneedle system for brain disease diagnosis and treatment and preparation method thereof | |
| CN1194696C (en) | Medicinal composition for injection, preparation containing said medicinal composition and its preparing process | |
| CN108272991A (en) | A kind of anaesthetic and its manufacturing process of removing heat from blood blood pressure lowering |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200110 |
|
| WD01 | Invention patent application deemed withdrawn after publication |